Belite Bio, Inc (BLTE)

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases with significant unmet medical need, such as Geographic Atrophy (GA), the late atrophic form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). Both GA and STGD1 cause progressive loss of vision leading to permanent blindness in almost all cases. The company's drug development pipeline also includes a small molecule, orally administered compound, LBS-009, intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

The company's lead product candidate, tinlarebant (a/k/a LBS-008), is an orally administered, once-a-day tablet intended as an early intervention for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. Currently, there are no FDA approved treatments for STGD1 and no approved orally administered treatments for GA. Tinlarebant has received Orphan Drug Designation in the United States and Europe, which provides for 7 years and 10 years, respectively, of market exclusivity from approval for STGD1, and has also received Rare Pediatric Disease Designation in the United States. In May 2022, the company received Fast Track designation for tinlarebant for the treatment of STGD1. The company holds a worldwide exclusive license of the RBP4 intellectual property portfolio from Columbia University, which contains disclosure directed to over 400 structurally distinct RBP4 antagonists under patent protection in major pharmaceutical markets worldwide, including the United States, the European Union, China, Australia, Japan, South Korea and India. As of the Latest Practicable Date, the company's portfolio of owned, co-owned, and in-licensed patents consisted of 27 issued U.S. patents (inclusive of allowed applications), 11 pending U.S. patent applications, 25 issued foreign patents (inclusive of allowed applications) and 44 pending foreign patent applications, providing protection in the United States and China, among other regions.

The company generates revenue through the development and potential commercialization of its product candidates, primarily tinlarebant and LBS-009, though it currently has no products approved for commercial sale and has not generated any revenue from product sales. The company's operations to date have been limited to financing and staffing, developing its technology, and conducting preclinical research and clinical trials for its product candidates. The company has financed its operations primarily through the issuance of its ordinary shares, including in the form of ADSs, pursuant to initial public offering, follow-on offerings, warrants, registered direct offerings, an At-the-Market (ATM) offering program, and a PIPE offering.

The company's lead product candidate, tinlarebant (a/k/a LBS-008), is an orally administered, once-a-day tablet intended as an early intervention for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. Tinlarebant was designed to be a potent and reversible RBP4 antagonist, reducing the amount of retinol entering the visual cycle thereby reducing the formation of bisretinoid toxins which will ultimately preserve the health of the retina. The company announced the top-line results of the Phase 3 DRAGON in December 2025 and expects to submit an NDA to the FDA in the second quarter of 2026. The company's drug development pipeline also includes LBS-009, a small molecule, orally administered compound intended for the treatment of metabolic diseases such as NAFLD, NASH, T2D, and gout.

The company's drug development pipeline includes LBS-009, a small molecule, orally administered compound intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. All of the company's product candidates (tinlarebant and LBS-009) are in clinical or preclinical development.

In December 2025, the company completed an underwritten follow-on offering of 2,272,727 ¹ ADSs, each representing one ordinary share, at a public offering price of $154.00 ² per ADS and for aggregate proceeds of approximately $350.0 million ³, with a 30-day option for the underwriters to purchase up to 340,909 ⁴ additional ADSs at the public offering price. As of the Latest Practicable Date, the underwriters have exercised their option in full. On September 8, 2025, the company entered into certain securities purchase agreements for a private placement in public equity financing with leading healthcare investors for the purchase and sale of 1,953,124 ⁵ ordinary shares, and warrants to purchase 1,953,124 ⁶ ordinary shares, at a purchase price of $64.00 ⁷ per ordinary share and accompanying warrant. On August 6, 2025, the company entered into a securities purchase agreement with an institutional investor, relating to the registered direct offering of 230,770 ⁸ ADSs and warrants to purchase 230,770 ⁹ ordinary shares, at a price of $65.00 ¹⁰ per ADS and accompanying warrant. On February 5, 2025, the company entered into a securities purchase agreement with an institutional investor, relating to the registered direct offering of 258,309 ¹¹ ADSs and warrants to purchase 258,309 ¹² ordinary shares, at a price of $58.07 ¹³ per ADS and accompanying warrant. In September 2022, the company received approval from NMPA to initiate the Phase 3 clinical trial of tinlarebant in adolescent STGD1 patients in China.

For the year ended December 31, 2025, the company reported a net loss of approximately $77.6 million ¹⁴, compared to net losses of approximately $36.1 million ¹⁵ and $31.6 million ¹⁶ for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2025, the company had an accumulated deficit of approximately $185.3 million ¹⁷. For the years ended December 31, 2023, 2024 and 2025, the net cash used in operating activities was approximately $29.8 million ¹⁸, $29.2 million ¹⁹ and $40.7 million ²⁰, respectively. The company has not generated any revenues from product sales.

The company announced the top-line results of the Phase 3 DRAGON in December 2025 and expects to submit an NDA to the FDA in the second quarter of 2026.

The company is developing tinlarebant to initially treat STGD1 and atrophic age-related macular degeneration (AMD), commonly known as Geographic Atrophy, or GA. The company is also considering a number of additional indications for tinlarebant, including the treatment of nonalcoholic steatohepatitis. The company has initiated clinical trials for tinlarebant in China, having received approval from NMPA in September 2022 to initiate the Phase 3 clinical trial in adolescent STGD1 patients. The company is conducting clinical trials, through third-party CROs, in multiple jurisdictions such as the United States, the United Kingdom, Germany, Netherlands, France, Belgium, Switzerland, Australia, Taiwan, Hong Kong, China, and Japan among others.

The company's drug development pipeline also includes LBS-009, a small molecule, orally administered compound intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

The company expects its expenses to increase in connection with its ongoing activities, particularly as it initiates new clinical trials of, initiates new research and preclinical development efforts for, and seeks marketing approval for, its product candidates. If the company obtains marketing approval for any of its product candidates, it may incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.

The company currently does not have cGMP manufacturing capabilities and is entirely dependent on third-party contractors, including contract manufacturing organizations (CMOs), to manufacture its product candidates for clinical trials, and expects to rely on third-party CMOs for the production of commercial quantities of its products in accordance with cGMP regulations upon obtaining regulatory and marketing approvals. As of December 31, 2025, the company's research and development team has expanded to 23 ²¹ employees, among which 10 ²² employees are responsible for clinical operations.

The company has financed its operations primarily through the issuance of its ordinary shares, including in the form of ADSs, pursuant to initial public offering, follow-on offerings, warrants, registered direct offerings, an At-the-Market (ATM) offering program, and a PIPE offering. On June 16, 2023, the company entered into a Sales Agreement for an ATM program for the offer and sale of ordinary shares represented by ADSs of an aggregate offering price up to $100 million ²³. The company sold 1,209,562 ²⁴ ADSs through the ATM program and received net proceeds from such sales of $72.6 million ²⁵ as of December 31, 2025. The company does not have any present plan to pay any dividends on its ordinary shares.

The company has recorded net cash outflow from operating activities since its inception and expects to continue to incur significant and increasing net operating losses for at least the next several years. The company's existing cash on hand will not be sufficient to fund all of the efforts that it plans to undertake or to fund the completion of development of any of its product candidates, and it will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources.

The company faces substantial competition in the biopharmaceutical industry, with competitors including major and specialty pharmaceutical companies and generic drug companies. Some competitors have ongoing clinical trials for product candidates that treat the same indications as tinlarebant. The company also faces risks related to the regulatory approval processes of the FDA, the TGA, the NMPA, the EMA, the PMDA and other comparable regulatory authorities, which are time-consuming and may evolve over time. The company is subject to risks related to conducting clinical trials in multiple jurisdictions, including differing regulatory requirements, foreign exchange fluctuations, and cultural differences in medical practice and clinical research.

Management's message emphasizes the company's focus on advancing novel therapeutics targeting degenerative retinal diseases with significant unmet medical need, particularly tinlarebant for STGD1 and GA. The company announced the top-line results of the Phase 3 DRAGON in December 2025 and expects to submit an NDA to the FDA in the second quarter of 2026. Key strategic priorities include completing clinical development and obtaining regulatory approval for tinlarebant, expanding the drug development pipeline (including LBS-009 for metabolic diseases), and securing additional financing to fund operations. Management acknowledges the company has a limited operating history and no history of commercializing pharmaceutical products, and that it will need to obtain substantial additional funding to complete the development and commercialization of its product candidates.

For the year ended December 31, 2025, the company reported a net loss of approximately $77.6 million ²⁷, compared to net losses of approximately $36.1 million ²⁸ for 2024 and $31.6 million ²⁹ for 2023. As of December 31, 2025, the company had an accumulated deficit of approximately $185.3 million ³⁰. The company has not generated any revenues from product sales. For the years ended December 31, 2023, 2024 and 2025, the net cash used in operating activities was approximately $29.8 million ³¹, $29.2 million ³² and $40.7 million ³³, respectively. As of December 31, 2025, the company had 39,339,960 ³⁴ ordinary shares outstanding. The company's net losses were significantly impacted by increased research and development expenses as it advanced its clinical trials, including the Phase 3 DRAGON trial for tinlarebant. The company's ability to use its net operating loss carryforwards may be subject to limitation; as of December 31, 2025, subsidiaries had U.S. net operating loss carryforwards for federal and state tax purposes of approximately $11.0 million ³⁵, with federal net operating loss carryforwards of $603 thousand ³⁶ incurred before January 1, 2018, beginning to expire in the years 2036 through 2037, and the remaining $8.8 million ³⁷ of federal net operating loss carryforwards, which are limited to 80% of taxable income, not expiring. The company had state net operating loss carryforwards of approximately $1.4 million ³⁸ that will begin to expire in the years 2036 through 2038.

The company's business is highly dependent on the success of its lead product candidate, tinlarebant, and if it is unable to develop, obtain marketing approval for, or successfully commercialize tinlarebant, its business could be harmed. All of the company's product candidates are in clinical or preclinical development, and if the company is unable to complete clinical development and obtain regulatory approval, its business will be materially harmed. The company has recorded net cash outflow from operating activities since its inception, with net cash used in operating activities of approximately $40.7 million ²⁶ for 2025, and will need to obtain additional financing to fund its operations. The company has a limited operating history and no history of commercializing pharmaceutical products. The regulatory approval processes of the FDA, the TGA, the NMPA, the EMA, the PMDA and other comparable regulatory authorities are time-consuming, and if the company is ultimately unable to obtain regulatory approval for its product candidates, its business will be substantially harmed. The company depends on intellectual property licensed from third parties, including an exclusive license agreement with Columbia University, and if it fails to comply with its obligations under these licenses or if the licenses are terminated, it could lose significant rights important to its business.